26 results on '"Ahn, J.B."'
Search Results
2. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
3. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
4. 417P Randomized phase II trial of upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy versus preoperative chemoradiotherapy followed by surgery and adjuvant chemotherapy in locally advanced rectal cancer: KCSG-CO14-10
5. 324P Effects of screening and treatment improvement on colon cancer survival over 20 years in Korea
6. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer
7. LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial
8. 618P Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer
9. The Benefit Of Locally Ablative Treatment In Lung Metastasis From Colorectal Cancer
10. 105P Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
11. 417P Lymph node (LN) retrieval as a high-risk factor in stage II and III colon cancer
12. Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial
13. A phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy
14. Phase III study of trifluridine/tipiracil versus placebo in Asian patients with metastatic colorectal cancer (TERRA study): Country subgroup
15. Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT)
16. Clinical manifestations and prognostic factors of bone metastasis in colorectal cancer
17. TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer
18. 88O - Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial
19. 568P - A phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy
20. 160P Significance of serum carcinoembryonic antigen despite normal preoperative levels in colorectal cancer patients receiving curative resection
21. LBA3_PR - Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI + bevacizumab versus FOLFIRI + bevacizumab (AXEPT)
22. 142O - Phase III study of trifluridine/tipiracil versus placebo in Asian patients with metastatic colorectal cancer (TERRA study): Country subgroup
23. 606P - Clinical manifestations and prognostic factors of bone metastasis in colorectal cancer
24. Metformin Use is Associated with Improved Survival in Diabetic Pancreatic Cancer Patients
25. 465PD - TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer
26. 699P - Metformin Use is Associated with Improved Survival in Diabetic Pancreatic Cancer Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.